27.04.2022 • NewsSanofi

Sanofi Teams up with McLaren Racing

Sanofi has joined forces with McLaren Racing in a move it hopes will accelerate its manufacturing efficiency and performance drive. As the French drugmaker’s CEO Paul Hudson put it, “we want to run our lines with the speed, precision and efficiency of a Formula One racing team.”

Following a successful pilot run in 2021, the now experienced team is extending its collaboration across multiple sites in seven   countries, covering more than 100 production lines, across all technologies. Sanofi hopes that working together with the racing company will provide insights and develop best practices for manufacturing that can be implemented across its global industrial network.

The Paris-based pharma major said experts from McLaren will work together with its own Industrial Affairs staff to continue  optimizing its manufacturing operations. This, it added, should enable its global network to better support the supply of its broad portfolio, as well as enhancing the delivery of its R&D pipeline.

A quick ”pedal to the metal” may be essential, as the Paris-based company is aiming for 25 new drug launches over the next five years.

Zak Brown, Chief Executive Officer, McLaren Racing

“We are thrilled to be...
Zak Brown, Chief Executive Officer, McLaren Racing “We are thrilled to be partnering with Sanofi. It is important that two global companies who share values work together to maximise performance. We look forward to continuing to collaborate with Sanofi to make a positive impact not only in manufacturing but to help Sanofi improve patients' lives.” (c) Sanofi

McLaren, which took on a similar project with Glaxo SmithKline some years ago, plans to use what Sanofi describes as a “a unique data-driven approach,” leveraging  its digital and analytical knowhow to help its partner better anticipate and resolve potential issues before they materialize.

Modeling simulation of production line changeovers and operations will be applied to the pharmaceuticals portfolio, in Sanofi’s words, “to optimize the famed pit stops of Formula 1 races.”

Beyond the technical collaboration, the drugmaker said the project with MacLaren will have a focus on the ”people dimension” of high performance, with  a “race-like mindset” emulating the competitive, fast paced environment of F1 racing to help accelerate improvements, learnings  and sharing of best practices individually and collectively across sites, fostering a “one Sanofi spirit.”

The idea of tapping the knowhow of manufacturers of fast cars has an earlier precedent. Since the beginning of the new millennium, Porsche Consulting, spun off from the luxury car manufacturer in the 1990s, has been applying its lean management concept to processes in the pharmaceutical and hospital sectors to improve the efficiency of their supply chains.

Author: Dede Williams, Freelance Journalist

(c) Sanofi
(c) Sanofi

Company

Logo:

Sanofi S.A.

46-48 Avenue de la Grande Armée
Paris
France

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.